In melanoma, higher BMAL1 is associated with higher T-lymphocyte infiltration, higher PD-1 and PD-L1 expression, better objective response to anti-PD1 immunotherapy and improved overall patient survival [66]. This evidence concerns the gene BMAL1 and melanoma.